Company intelligence / Profile preview

上海循曜生物科技

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Xunyao Biotech is a Shanghai-based clinical-stage biotechnology company focused on developing transformative therapies for hematological disorders and rare diseases. Founded in 2019 by Dr. Liu Junling, the company utilizes a proprietary platelet-targeted technology platform to create innovative gene and cell therapies. Its lead programs, XY001 and XY002, target Hemophilia A and B respectively, aiming to provide durable treatment options through specialized expression systems. Xunyao also develops biologics for thrombocytopenia and other blood-related conditions. The company has attracted significant investment from prominent firms like Sherpa Healthcare Partners and IDG Capital to accelerate its clinical pipeline.

Therapeutic areas: Hematology
Modalities: Gene therapyBiologicCell therapyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on 上海循曜生物科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 上海循曜生物科技.

Explore the full profile